| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Insight USA is a California, MD-based company in the Software and Internet sector.
@PCCInnovation leverages data scientists, expert clinicians and social determinants of health to better support under-served populations across our communities.
Start FREE TRIAL Start FREE TRIALContact SalesSee if Your Bank or Credit Union Offers FINSYNC See if Your Bank or Credit
Union Offers FINSYNC
Federal market data and analysis for investors and strategic decision makers.